Caldera Pharmaceuticals, Inc.

Los Alamos, NM 87544
http://www.cpsci.com
16 Employees

SBIR Award Summary

Total Number of Awards 27
Total Value of Awards $8.37MM
First Award Date 08/01/06
Most Recent Award Date 09/22/15

Key Personnel

Last Name Name Awards Contact
Birnbaum Dr. Eva Birnbaum 6 Message
Harris Dr. Michael Harris 5
Warner Benjamin Warner 16 Message
BENJAMIN BENJAMIN 1 Message
PETERSON LORI PETERSON 1

27 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/15 - 06/21/16

Caldera Pharmaceuticals will develop systemic targeted radionuclide therapy (STRT) with advantages of attacking multiple tumor systems to combat resistance mechanisms, using radiation cytotoxicity, and specificity of tumor-targeting agents. Caldera XRpro technology consisting of label-free, high-throughput screening/HTS instruments, microarrays,...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-044
Budget: 07/01/15 - 06/30/16

DESCRIPTION (provided by applicant): Caldera aims to develop an inexpensive, stable, selective, decorporation (decorp) agent for cesium-137 (Cs-137). Cs-137 is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation/nuclear emergencies, high priority for DHHS / NIH / NIAID / DAIT, and a ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-044
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): Caldera aims to develop an inexpensive, stable, selective, decorporation (decorp) agent for cesium-137 (Cs-137). Cs-137 is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation/nuclear emergencies, high priority for DHHS / NIH / NIAID / DAIT, and a ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-093
Budget: 08/01/13 - 07/31/14

DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project consists of the necessary steps for submission of an Emergency Use Authorization (EUA) or Investigational New Drug (IND) application to the US FDA. A g...

Phase 1 SBIR

Agency: Air Force
Topic: AF121-220
Budget: 08/13/12 - 05/12/13
PI: BENJAMIN

ABSTRACT: Caldera Pharmaceuticals proposes to develop physiologic biomarkers requested by the US Air Force to quantify workplace exposure to hexavalent chrome (Cr+6). Exposure to Cr+6 is dangerous and unwanted, because it is a primary carcinogen (class 1 International Agency for Research on Cancer / IARC) and a known lung cancer carcinogen. Chro...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-093
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project consists of the necessary steps for submission of an Emergency Use Authorization (EUA) or Investigational New Drug (IND) application to the US FDA. A g...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AT-07-003
Budget: 09/30/11 - 09/29/12

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals uses protein fractionation techniques and XRpro technology to determine protein CAM/metabolite binding as a means to determine adherence to CAM regimens in NCCAM clinical trials. Caldera will use their high-throughput proteomics technology to identify CAM Adherence Biomarkers (CABs) u...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-093
Budget: 08/24/11 - 07/31/12

DESCRIPTION (provided by applicant): This Phase II project continues the successful Phase I discovery of novel decorporation agents that are selective for radioactive strontium (Sr). This project consists of the necessary steps for submission of an Emergency Use Authorization (EUA) or Investigational New Drug (IND) application to the US FDA. A g...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-187
Budget: 08/06/10 - 08/05/12

DESCRIPTION (provided by applicant): Caldera Pharmaceuticals will develop quantitative biomarker assays for a set of carcinogens. In Phase I, Caldera will demonstrate the feasibility of using its novel XRpro(R) technology to extract, concentrate, quantify, and characterize carcinogens from biological samples. This will also identify protein addu...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-110
Budget: 03/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for characterizing transient protein complexes. MAPK pathways play important roles in cellular differ...

Load More